The kisspeptin trial record, section by section

The short version

Kisspeptin — produced from the KISS1 gene — is the master upstream signal that turns on the reproductive hormone axis. It binds KISS1R (GPR54) on hypothalamic GnRH neurons, which triggers a calcium signaling cascade that fires off pulsatile GnRH into the portal circulation. The pituitary responds with LH and FSH, which drive sex-steroid production in the gonads. The research below covers this mechanism in detail, then walks through the individual trial findings from the 20-year Imperial College record: hypothalamic amenorrhea, IVF triggering, sexual desire in men and women, bone formation markers, PCOS, liver metabolism, and the 2025 intranasal delivery breakthrough. All dose figures and outcome numbers come from the registered protocols cited inline — they are research context, not clinical guidance.

KISS1R signaling: the molecular mechanism

All kisspeptin isoforms bind KISS1R (GPR54) — a G-protein-coupled receptor coupled to the Gq/11 signaling pathway. Receptor activation triggers phospholipase C, which cleaves phosphatidylinositol-4,5-bisphosphate into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes intracellular calcium; DAG activates protein kinase C. The combined signal depolarizes GnRH neurons in the hypothalamus, causing them to fire and release GnRH in pulses into the hypothalamo-pituitary portal circulation. KISS1R activation also phosphorylates ERK1/2 and p38 MAPK, though the downstream transcriptional consequences of these MAPK signals in GnRH neurons are less fully characterized ^[9].

The duration of KISS1R signaling determines the physiological outcome. Pulsatile kisspeptin, delivered in short bursts, sustains pulsatile GnRH and therefore pulsatile LH. Continuous, non-pulsatile kisspeptin — at high doses or through prolonged infusion — causes receptor internalization (KISS1R desensitization) and blunted gonadotropin response. This is the same fundamental pharmacodynamic principle that governs GnRH agonist therapy: continuous agonism eventually suppresses the very axis it initially stimulates ^[10].

The compund class status of the human genetic data is striking in its specificity. Homozygous and compound heterozygous loss-of-function mutations in KISS1R cause idiopathic hypogonadotropic hypogonadism — absent puberty, anosmia in some cases, and the failure of the hypothalamic-pituitary-gonadal (HPG) axis to ever establish normal function. Gain-of-function mutations in KISS1R cause central precocious puberty. The same receptor, at the same anatomical site, drives opposite phenotypes depending on whether signaling is absent or constitutively active ^[10].

Beyond the reproductive axis, KISS1R is expressed in hepatocytes, where its activation engages AMPK to suppress lipogenesis via SREBP-1c downregulation. A separate pathway in epithelial cancer cells involves kisspeptin inhibition of FAK/Rho GTPase → MMP-2/MMP-9 activity, a molecular mechanism consistent with the originally identified tumor-metastasis suppressor function of the KISS1 gene ^[14].

KNDy neurons: the GnRH pulse generator

The mechanistic understanding of kisspeptin's physiological role advanced significantly with the identification of KNDy neurons — hypothalamic neurons in the arcuate nucleus (ARC) that co-express Kisspeptin, Neurokinin B, and Dynorphin A. These three neuropeptides form an autosynaptic loop. Neurokinin B signals through the NK3R receptor on neighboring KNDy neurons in a stimulatory direction, synchronizing the population into burst activity. Dynorphin A signals through kappa-opioid receptors in an inhibitory direction, terminating each synchronized burst. Kisspeptin is the output signal — released from KNDy neurons to activate KISS1R on GnRH neuron terminals, triggering GnRH release ^[9].

The pulse-generator function of KNDy neurons was demonstrated directly in rodent knockout-rescue models. Animals with kisspeptin expression ablated in the arcuate nucleus failed to establish pulsatile GnRH secretion and were infertile. Restoration of kisspeptin expression specifically in arcuate KNDy neurons fully rescued pulsatile fertility — confirming that arcuate kisspeptin is necessary and sufficient for normal reproductive axis function in these models ^[9].

A second, anatomically distinct population of kisspeptin neurons in the anteroventral periventricular nucleus (AVPV) mediates a different function: the positive estradiol-feedback LH surge that triggers ovulation. In the rodent, rising estradiol primes AVPV kisspeptin neurons to fire a large, synchronized burst of GnRH, producing the mid-cycle LH surge. In humans, a functionally analogous AVPV-like population is proposed, with neurokinin B fine-tuning the hypothalamic contribution to ovulation precision ^[17]. The ARC and AVPV populations are thus functionally complementary: ARC KNDy drives the pulsatile baseline, AVPV drives the ovulatory surge.

Kisspeptin and LH pulses are temporally coupled at lag-0 in observational studies of human women — they co-secrete synchronously, not sequentially. In women with functional hypothalamic amenorrhea, cortisol levels inversely correlate with endogenous kisspeptin levels, providing direct human evidence that HPA-axis stress signaling suppresses the KNDy pulse generator ^[12].

Human reproductive trials: hypothalamic amenorrhea and IVF

The first human kisspeptin study, published in the Journal of Clinical Endocrinology & Metabolism in 2005, established proof-of-concept: intravenous kisspeptin-54 at 0.25–12 pmol/kg/min produced a dose-dependent increase in serum LH in healthy adult men, with smaller increases in FSH and testosterone — the first demonstration of kisspeptin bioactivity in humans ^[1].

A 2014 study extended this to women with hypothalamic amenorrhea — a reversible suppression of the HPG axis that affects women under conditions of chronic energy deficit, psychological stress, or extreme exercise. Continuous intravenous kisspeptin-54 infusion at intermediate doses (0.01–1.00 nmol/kg/h, 8–10 hours) temporarily restored pulsatile LH secretion. At optimal doses, LH pulse number increased 3-fold and pulse secretory mass increased 6-fold versus vehicle. Only the highest dose (1.00 nmol/kg/h) produced desensitization, consistent with the dose-duration pharmacodynamics of KISS1R ^[2].

The head-to-head comparison of kisspeptin-10 and kisspeptin-54 in healthy men (Jayasena et al., Human Reproduction, 2015) found that the two isoforms produced comparable LH and FSH area-under-the-curve responses at equivalent molar doses (0.1, 0.3, and 1.0 nmol/kg/h IV over 3 hours), despite the large difference in molecular weight and plasma half-life. GnRH at equivalent doses was approximately 2–3× more potent than either kisspeptin isoform for LH release and approximately 2× more potent for FSH ^[3]. This positions kisspeptin as an upstream effector rather than a substitute for GnRH agonism — the signaling hierarchy is KISS1R → GnRH neuron → GnRH → pituitary, not a parallel pathway.

In IVF, conventional oocyte maturation triggering uses human chorionic gonadotropin (hCG), which carries a risk of ovarian hyperstimulation syndrome (OHSS) in high-responder patients. A Phase 2 randomized trial tested kisspeptin-54 as an alternative trigger. A single subcutaneous bolus at 12.8 nmol/kg (the optimal dose identified across arms of 3.2, 6.4, 9.6, and 12.8 nmol/kg) triggered oocyte maturation in 95% of high-OHSS-risk patients. No woman developed moderate, severe, or critical OHSS. The clinical pregnancy rate was 53% and live birth rate per transfer was 45% ^[4].

A subsequent trial improved the oocyte maturation yield by adding a second dose. A second kisspeptin-54 injection at 9.6 nmol/kg SC, administered 10 hours after the first trigger dose, increased the proportion of patients achieving ≥60% mature oocyte yield from 45% (single dose) to 71% (double dose), without increasing OHSS incidence ^[5].

Human trials: sexual desire, bone, and safety

Beyond the reproductive axis, the Imperial College group has investigated kisspeptin's effects on sexual desire, bone metabolism, and anxiety.

For hypoactive sexual desire disorder (HSDD) in men, a double-blind randomized trial (n=32 completers) used fMRI to measure brain activity during sexual processing tasks. IV kisspeptin-54 infusion (1 nmol/kg/h, 75 minutes) significantly altered brain activity in sexual-processing networks (Cohen d=0.81, p=0.003) relative to placebo and increased penile tumescence by up to 56% more than placebo. Participants reported significantly increased happiness about sex (p=0.02) ^[6].

A parallel trial in premenopausal women with HSDD (n=32) found that IV kisspeptin-54 infusion altered fMRI activation in the inferior frontal gyrus, postcentral and supramarginal gyri, and temporoparietal junction during sexual processing tasks. Enhanced hippocampal activity correlated with reduced baseline sexual distress scores. No adverse effects were reported across the trial ^[7].

Bone formation was measured after acute kisspeptin IV infusion in 26 healthy men (Comninos et al., JCEM, 2022). Total osteocalcin — a sensitive marker of osteoblast activity — rose 20.3% at peak, and carboxylated osteocalcin rose 24.3%. In parallel in vitro studies using human bone marrow-derived cells, kisspeptin elevated osteoblast alkaline phosphatase by 41% and inhibited osteoclast resorptive activity by up to 53% in a dose-dependent manner ^[8].

The 2025 safety study — the largest kisspeptin RCT to date, with 95 participants (63 male, 32 female) — found that IV kisspeptin-54 (1 nmol/kg/h, 75 minutes) robustly elevated LH without affecting anxiety measures (STAI questionnaire), cortisol, blood pressure, or heart rate. This study was specifically designed to test for anxiogenic effects, given the compound's known effects on brain circuits. No adverse effects were recorded [cited in recent studies].

Also in 2025, the first demonstration of intranasal kisspeptin delivery was published in eBioMedicine. At 12.8 nmol/kg intranasal, mean LH increased 4.4 ± 0.6 IU/L (p=0.002 versus placebo) in healthy men. The same formulation was effective in women and in hypothalamic amenorrhea patients. The nasal spray preparation was stable for 60 days at 4°C. No adverse events were reported across all groups [cited in recent studies].

Non-reproductive research: PCOS, liver, and cancer

Polycystic ovary syndrome (PCOS) is characterized by elevated LH pulse frequency, androgen excess, and often elevated endogenous kisspeptin. A systematic review of 29 interventional and observational studies found kisspeptin elevated in 8 of 12 studies of PCOS women versus controls, most prominently in lean PCOS phenotypes with elevated LH and normal body weight. Elevated kisspeptin correlates positively with LH amplitude and testosterone in these phenotypes ^[11]. The implication is mechanistically consistent: aberrant KNDy neuron hyperactivity drives elevated GnRH pulse frequency → elevated LH → androgen overproduction. Whether kisspeptin is causal or a downstream marker in PCOS neuroendocrinology remains under investigation.

Hepatic KISS1R signaling has been studied as a metabolic target. Liver-specific KISS1R knockout worsened steatosis in high-fat diet mice. Administration of a kisspeptin agonist (TAK-448, 0.3 nmol/hr continuous infusion) significantly reduced hepatic triglycerides and fibrosis progression in the DIAMOND mouse model of non-alcoholic fatty liver disease. In human NAFLD patients, elevated plasma kisspeptin and elevated hepatic KISS1/KISS1R expression were documented relative to controls, suggesting a potential compensatory upregulation ^[13].

As a metastasis suppressor, kisspeptin acts through KISS1 gene expression to suppress FAK/Rho GTPase signaling and downregulate MMP-2 and MMP-9, the matrix metalloproteinases responsible for degrading the extracellular matrix and enabling tumor invasion. In endometrial cancer cell lines, kisspeptin-10 inhibited cell migration and invasion, downregulated N-cadherin and beta-catenin (mesenchymal markers), and upregulated E-cadherin (epithelial marker) — reversing the epithelial-mesenchymal transition ^[14]. These findings are currently limited to in vitro cell-culture models; no clinical trials have evaluated kisspeptin for oncology indications in humans.

A 2024 systematic review covering 29 interventional clinical trials registered through 2023 concluded that the kisspeptin compound class spans therapeutic candidates for secondary amenorrhea, puberty regulation, IVF triggering, pregnancy complication biomarkers, fertility management, lactation, and metabolic disorders, with a favorable safety profile across reviewed indications ^[16].